MODERN ORAL ANTICOAGULANT TREATMENT IN PATIENTS
WITH ATRIAL FIBRILLATION AND HEART FAILURE: INSIGHTS
FROM THE CLINICAL PRACTICE
OTILIA ANCA ȚICA 1,2#, OVIDIU ȚICA 2,3#*, LIANA ANTAL 2#, ADRIAN HATOS 4#, MIRCEA IOACHIM POPESCU 1,2#, ANCA PANTEA STOIAN 5#, OVIDIU GABRIEL BRATU 5,6#, MIHNEAALEXANDRU GĂMAN 5#, SILVIU MIREL PIȚURU 5#, CAMELIA CRISTINA DIACONU 5,7#
1Emergency County Clinical Hospital of Oradea, Cardiology Clinic, Gheorghe Doja Street, no. 65, Oradea, Romania
2Faculty of Medicine and Pharmacy, University of Oradea, 1st of December Square, no 10, Oradea, Romania
3Emergency County Clinical Hospital of Oradea, Pathology Department, Gheorghe Doja Street, no. 65, Oradea, Romania
4Faculty of Sociological Sciences, University of Oradea, Romanian Army Street no 5, Oradea, Romania
5University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
6Emergency University Central Military Hospital, Bucharest, Romania
7Clinical Emergency Hospital of Bucharest, Internal Medicine Clinic, Bucharest, Romania
*corresponding author: ovidiu.tica@gmail.com
#All authors had equal contribution
DownloadDownload Full Article

Abstract:
Atrial fibrillation (AF) and heart failure (HF) are some of the most common cardiovascular pathologies of our century. These
two pathologies can frequently coexist, raising particular diagnostic and therapeutic problems. Patients with AF and HF have
a high thromboembolic risk, which justifies the indication of long-term anticoagulant therapy. Vitamin K antagonists
(acenocoumarol) have long been the only oral therapeutic option for the prevention of embolic events in this category of
patients. However, the great variability of their anticoagulant effect, with the necessity of monthly monitoring of the
coagulation parameters, led to the search of newer therapeutic options, with a more predictable effect and reduced side
effects. Modern therapeutic alternatives, such as non-vitamin K oral agents (dabigatran, rivaroxaban, apixaban, edoxaban),
have appeared. In this study, we aimed to evaluate the role of oral anticoagulant therapy, especially non-vitamin K, in
managing patients with both pathologies.






Top